CCL2 and COVID-19: This was further corroborated by data demonstrating that although COVID-19 patients exhibited increased pro-inflammatory cytokine levels (e.g., IL-16, IL-10, and monocyte chemoattractant protein-1, MCP-1), these levels were not as high as in other non-COVID-19 patients suffering from cytokine-release syndrome [66].